Latest / Stock Movers / Novo Says It’s Suing Hims; Lilly Strikes Deal for Biotech Orna; Alphabet Looks to Raise About $15 Billion
Transcript
- 0:00Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market
- 0:13Speaker 1: harnessing the power of Bloomberg data.
- 0:16Speaker 2: Let's take a look at some stacks in the move today.
- 0:19Speaker 3: Jem Tucker didn't tell me that let's start with the
- 0:22Speaker 3: most active Hymns and Hers And frankly, I don't know
- 0:26Speaker 3: how they get away with some of this stuff. And anyway,
- 0:28Speaker 3: Novo Nordis is suing Hymns in Hers Health for making
- 0:32Speaker 3: knockoffs of the obesity medications, even as HIMS scrap plans
- 0:37Speaker 3: to sell a copycat version of Wigovi the pill. Novo
- 0:42Speaker 3: has argued Hyms is breaching its US patent on semagluetide,
- 0:46Speaker 3: the active ingredient in the blockbuster medicines. It's also built
- 0:50Speaker 3: the rival products as potentially dangerous for consumers. The lawsuit
- 0:56Speaker 3: marks and escalation of Novo's spat with Hyms. This is
- 1:00Speaker 3: at the Telehealth Platform retreat on Saturday. They said they
- 1:03Speaker 3: weren't going to go through with it. It said was
- 1:05Speaker 3: stop offering the cheaper versions of the new Goovi pill.
- 1:08Speaker 3: The Hymns decision to launch a knockoff with Goovie pill
- 1:11Speaker 3: was a step too far. This according the general counsel
- 1:15Speaker 3: at NOVO, John Kuckelman, said in an interview, last week's
- 1:20Speaker 3: announcement was egregious, as he put it, and was definitely
- 1:24Speaker 3: a tipping point of the two companies. This scrap a
- 1:27Speaker 3: partnership you were called last year, and the relationship has
- 1:30Speaker 3: grown increasingly acrimonious.
- 1:33Speaker 2: That Serena Williams was great yesterday. I can't remember what
- 1:36Speaker 2: she was selling, but it's like I lost thirty four pounds.
- 1:40Speaker 3: Yeah, after motherhood, you know.
- 1:43Speaker 2: Esus turned to me and said, next ye, next gen.
- 1:46Speaker 3: All right. Deal news this morning, Eli Lilly gonna buy
- 1:50Speaker 3: closely held biotech or A Therapeutics. The price tag here,
- 1:55Speaker 3: well it's just two point just two point four billion
- 1:57Speaker 3: in cash. But it's the second deal in many days
- 2:01Speaker 3: as Lily's trying to expand the pipeline beyond the blockbuster
- 2:04Speaker 3: obesity drug zet pound or A, developing a new class
- 2:07Speaker 3: of treatments for certain autoimmune diseases like rheumatory arthritis and MS.
- 2:14Speaker 3: The biotech company it's based in Watertown, Massachusetts. They've struck
- 2:18Speaker 3: licensing deals with other companies, including Vertex pharmaceuticas and Merk.
- 2:23Speaker 3: So the Lily orned deal is going to include upfront
- 2:26Speaker 3: payments as well as payouts based on meeting certain milestones.
- 2:32Speaker 3: While the Lilies dominated the ultra competitive obesity market with zetbound,
- 2:36Speaker 3: the company is trying to build out its pipeline.
- 2:39Speaker 2: Is this stock Movers all obesity?
- 2:41Speaker 3: I think yeah, I mean there is a theme here.
- 2:45Speaker 2: Give us one more quick, what do you get?
- 2:47Speaker 3: Well, let's follow up on alphabet and just flesh this
- 2:50Speaker 3: out a little. They're going to raise fifteen billion with
- 2:53Speaker 3: a high grade dollar bond sale.
- 2:56Speaker 1: So yeah.
- 2:59Speaker 2: Series borrowings yep.
- 3:02Speaker 3: Massive clown computing companies, the hyperscalers we know them as
- 3:06Speaker 3: expected to spend more than six hundred and fifty billion
- 3:09Speaker 3: dollars this year to expand AI infestry.
- 3:12Speaker 1: That was great reporting by Bloomberg News last week putting
- 3:14Speaker 1: that all together to come up that that's six hundred
- 3:16Speaker 1: and fifty billion dollar numbers.
- 3:17Speaker 2: Yeah.
- 3:18Speaker 3: I watering.
- 3:21Speaker 2: Well. Their long maturity, some of them thirty two one
- 3:24Speaker 2: hundred years. As one of the prince I saw John Tucker.
- 3:26Speaker 2: Thank you so much. Stock Movers. It is a.
- 3:28Speaker 1: Podcast, the Stock Movers Report from Bloomberg Radio. Check back
- 3:34Speaker 1: with us throughout the day. For the latest roundup of
- 3:36Speaker 1: companies making news on Wall Street, and for the latest
- 3:40Speaker 1: market moving headlines. Listen to Bloomberg Radio Live, catch us
- 3:44Speaker 1: on YouTube, Bloomberg dot com, and on Applecarplay and Android
- 3:48Speaker 1: Auto with the Bloomberg Business app.